CTRI/2022/09/045465已完成2 期
A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicentric, Phase II Clinical Study to Evaluate Safety and Efficacy of Azelastine 0.1% Nasal Spray in Non-hospitalized Patients with Mild COVID-19 Infection
rsapharm Arzneimittel GmbH0 个研究点目标入组 294 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 294
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients must meet all the following inclusion criteria in order to participate in this study:
- •1.Patients or legally accepted representative (LAR) provides informed consent prior to initiation of any study procedures.
- •2.Patients or LAR understands and agrees to comply with planned study procedures.
- •3.Male or female patients =18 years of age at the time of enrollment.
- •4.Patients with positive Rapid Antigen Test for SARS-CoV-2.
- •5.Willing to provide nasopharyngeal swabs
- •6.For females: non-pregnant, non-lactating with adequate contraception until Day 11, or females unable to bear children (i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period).
排除标准
- •Patient’s meeting any of the following criteria are not eligible for the study:
- •1.Having any contraindication for the use of azelastine (including hypersensitivity to the active substance or other ingredients).
- •2.Patients requiring hospitalization (social admission will be an exception wherein the patient could have mild symptoms requiring quarantine, but no facility is available for the same and thereby hospitalization).
- •3.Patients with moderate (peripheral capillary oxygen saturation [SpO2] <93%) or severe COVID-19 disease (SpO2 <90%) based on MoH FW guidelines, Revised on 23-Sep-2021.
- •4.Any concurrent antihistamine therapy (systemic as well).
- •5.Any concurrent nasal spray or any nasalia including nasal lavage fluid.
- •6.Inability to administer the nasal spray.
- •7.Patients with nasal structure abnormalities, including nasal ulceration, nasal mucosal erosion, large nasal polyps and marked septal deviations that significantly interfere with nasal airflow.
- •8.Patients with alcohol or drug dependence.
- •9.Patients receiving any concurrent anti-COVID therapy (including off-label use).
- •10.Where, in the opinion of the investigator, participation in this study will not be in the best interest of the patient or any other circumstances that prevent the patient from participating in the study safely
- •11.Specific vulnerable patients: patients who are detained or committed to institutions by law court or by legal authorities, such as psychiatric wards, prisons, or other state institutions.
- •12.Patients with a history of psychiatric illness.
- •13.Simultaneous participation in other clinical studies or previous participation within 30 days before inclusion.
- •14.Being in any relationship or dependence with the Sponsor, Contract Research Organization (CRO), and/or Investigator.
- •Note: If the RT-PCR test is negative for a patient, that patient will be taken off from the study.
研究者
相似试验
已完成
不适用
A clinical trial to study the effectiveness of Dermacyte® A clinical trial to study the effectiveness of Dermacyte® Cosmetic Cream in reducing itching, redness and swelling due to Histamine.CTRI/2012/01/002360Oxygen Biotherapeutics Inc30
进行中（未招募）
1 期
Clinical study to evaluate the safety and tolerability of treatment with BT063 versus Placebo in Subjects with Systemic Lupus Erythematosus (BT063 in SLE)MedDRA version: 19.1Level: LLTClassification code 10042947Term: Systemic lupus erythematosus syndSystem Organ Class: 100000004859Systemic Lupus ErythematosusEUCTR2014-005526-35-PLBiotest AG36
进行中（未招募）
不适用
A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, International Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma (PATHWAY) - PATHWAYpost-resection hepatocellular carcinomaMedDRA version: 6.1Level: PTClassification code 10019701EUCTR2007-005011-25-ITPROGEN PHARMACEUTICALS LIMITED600
尚未招募
4 期
A clinical trial to study the effect of Ashwagandha on Transient InsomniaCTRI/2020/12/029647International Institute of Sleep Sciences
尚未招募
Unknown
Effect of GLUBLOC™ on blood glucose level after consumption of food among healthy individuals.CTRI/2023/07/055757Vidya Herbs Pvt Ltd